WR Hambrecht raises its price target on Array Biopharma Inc. (Nasdaq: ARRY) from $10 to $17 following strong AZD6244 phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE